CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 97 filers reported holding CABALETTA BIO INC in Q3 2023. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,004,115 | +52.6% | 1,774,252 | +29.5% | 1.28% | +89.2% |
| Q2 2023 | $17,690,560 | +680.0% | 1,370,299 | +399.6% | 0.68% | +592.9% |
| Q1 2023 | $2,268,064 | -47.2% | 274,252 | -40.9% | 0.10% | -44.3% |
| Q4 2022 | $4,294,331 | +848.0% | 464,252 | -33.3% | 0.18% | +877.8% |
| Q3 2022 | $453,000 | -38.6% | 696,377 | 0.0% | 0.02% | -35.7% |
| Q2 2022 | $738,000 | -47.8% | 696,377 | 0.0% | 0.03% | -36.4% |
| Q1 2022 | $1,414,000 | -46.4% | 696,377 | 0.0% | 0.04% | -26.7% |
| Q4 2021 | $2,639,000 | -68.8% | 696,377 | 0.0% | 0.06% | -59.5% |
| Q3 2021 | $8,468,000 | +41.4% | 696,377 | -0.0% | 0.15% | +66.3% |
| Q2 2021 | $5,989,000 | -22.5% | 696,378 | 0.0% | 0.09% | -18.3% |
| Q1 2021 | $7,730,000 | -55.1% | 696,378 | -49.5% | 0.11% | -47.6% |
| Q4 2020 | $17,201,000 | +14.4% | 1,378,319 | -0.6% | 0.21% | -24.6% |
| Q3 2020 | $15,031,000 | -5.4% | 1,386,584 | -2.8% | 0.28% | -5.8% |
| Q2 2020 | $15,884,000 | +52.6% | 1,425,896 | 0.0% | 0.29% | +0.3% |
| Q1 2020 | $10,409,000 | -48.0% | 1,425,896 | -0.4% | 0.29% | -38.9% |
| Q4 2019 | $20,001,000 | – | 1,431,696 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |